MAPT and Alzheimer disease: SNHG8 was significantly reduced in FTLD-tau caused by MAPT IVS10 + 16 or p.P301L (Fig. 3B, Supplementary Table 12); a primary sporadic tauopathy, progressive supranuclear palsy (Fig. 3C, Supplementary Table 13); and a secondary tauopathy, Alzheimer’s disease (Fig. 3C, Supplementary Table 14).